182 related articles for article (PubMed ID: 21419438)
21. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
Sengupta S; Myers RP; Slezak JM; Bergstralh EJ; Zincke H; Blute ML
J Urol; 2005 Dec; 174(6):2191-6. PubMed ID: 16280762
[TBL] [Abstract][Full Text] [Related]
22. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
Haese A; Dworschack RT; Partin AW
J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
[TBL] [Abstract][Full Text] [Related]
23. Editorial comment on: prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review.
Malavaud B
Eur Urol; 2008 Sep; 54(3):515-6. PubMed ID: 18585850
[No Abstract] [Full Text] [Related]
24. Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer.
Punglia RS; Cullen J; McLeod DG; Chen Y; D'Amico AV
Cancer; 2007 Nov; 110(9):1973-8. PubMed ID: 17886252
[TBL] [Abstract][Full Text] [Related]
25. Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators.
Nam RK; Kattan MW; Chin JL; Trachtenberg J; Singal R; Rendon R; Klotz LH; Sugar L; Sherman C; Izawa J; Bell D; Stanimirovic A; Venkateswaran V; Diamandis EP; Yu C; Loblaw DA; Narod SA
J Clin Oncol; 2011 Aug; 29(22):2959-64. PubMed ID: 21690464
[TBL] [Abstract][Full Text] [Related]
26. Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria?
Ploussard G; Salomon L; Xylinas E; Allory Y; Vordos D; Hoznek A; Abbou CC; de la Taille A
J Urol; 2010 Feb; 183(2):539-44. PubMed ID: 20006888
[TBL] [Abstract][Full Text] [Related]
27. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance.
Ploussard G; Durand X; Xylinas E; Moutereau S; Radulescu C; Forgue A; Nicolaiew N; Terry S; Allory Y; Loric S; Salomon L; Vacherot F; de la Taille A
Eur Urol; 2011 Mar; 59(3):422-9. PubMed ID: 21156337
[TBL] [Abstract][Full Text] [Related]
28. Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for T1c prostate cancer.
Tanaka N; Fujimoto K; Yoshikawa M; Tanaka M; Hirao Y; Kondo H; Saito I
Hinyokika Kiyo; 2007 Jul; 53(7):459-65. PubMed ID: 17702178
[TBL] [Abstract][Full Text] [Related]
29. Repeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA?
Connolly D; Black A; Murray LJ; Nambirajan T; Keane PF; Gavin A
Prostate Cancer Prostatic Dis; 2009; 12(1):47-51. PubMed ID: 18762815
[TBL] [Abstract][Full Text] [Related]
30. Active surveillance with selective delayed intervention for favorable risk prostate cancer.
Klotz L
Urol Oncol; 2006; 24(1):46-50. PubMed ID: 16414494
[TBL] [Abstract][Full Text] [Related]
31. Editorial comment on: prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review.
Rittmaster R
Eur Urol; 2008 Sep; 54(3):514-5. PubMed ID: 18585846
[No Abstract] [Full Text] [Related]
32. Ki67 and BUBR1 may discriminate clinically insignificant prostate cancer in the PSA range <4 ng/ml.
Nagao K; Yamamoto Y; Hara T; Komatsu H; Inoue R; Matsuda K; Matsumoto H; Hara T; Sakano S; Baba Y; Matsuyama H
Jpn J Clin Oncol; 2011 Apr; 41(4):555-64. PubMed ID: 21233104
[TBL] [Abstract][Full Text] [Related]
33. Percentages of positive cores, cancer length and Gleason grade 4/5 cancer in systematic sextant biopsy are all predictive of adverse pathology and biochemical failure after radical prostatectomy.
Suekane S; Noguchi M; Nakashima O; Yamada S; Kojiro M; Matsuoka K
Int J Urol; 2007 Aug; 14(8):713-8. PubMed ID: 17681061
[TBL] [Abstract][Full Text] [Related]
34. Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3).
Aus G; Becker C; Lilja H; Khatami A; Pihl CG; Hugosson J
Scand J Urol Nephrol; 2003; 37(6):466-70. PubMed ID: 14675918
[TBL] [Abstract][Full Text] [Related]
35. [Diagnostic value of tissue and serum prostate specific antigen in prostate cancer].
Medvedev VL
Voen Med Zh; 2004 Feb; 325(2):50-4. PubMed ID: 15101295
[No Abstract] [Full Text] [Related]
36. Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer.
Gofrit ON; Zorn KC; Taxy JB; Lin S; Zagaja GP; Steinberg GD; Shalhav AL
J Urol; 2007 Nov; 178(5):1925-8. PubMed ID: 17868725
[TBL] [Abstract][Full Text] [Related]
37. Personalized prediction of tumor response and cancer progression on prostate needle biopsy.
Donovan MJ; Khan FM; Fernandez G; Mesa-Tejada R; Sapir M; Zubek VB; Powell D; Fogarasi S; Vengrenyuk Y; Teverovskiy M; Segal MR; Karnes RJ; Gaffey TA; Busch C; Haggman M; Hlavcak P; Freedland SJ; Vollmer RT; Albertsen P; Costa J; Cordon-Cardo C
J Urol; 2009 Jul; 182(1):125-32. PubMed ID: 19450827
[TBL] [Abstract][Full Text] [Related]
38. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.
Eggener SE; Roehl KA; Yossepowitch O; Catalona WJ
J Urol; 2006 Oct; 176(4 Pt 1):1399-403. PubMed ID: 16952643
[TBL] [Abstract][Full Text] [Related]
39. Re: Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?
Ansari MS
J Urol; 2002 Jul; 168(1):200; author reply 200-1. PubMed ID: 12050532
[No Abstract] [Full Text] [Related]
40. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter.
Ahyai SA; Graefen M; Steuber T; Haese A; Schlomm T; Walz J; Köllermann J; Briganti A; Zacharias M; Friedrich MG; Karakiewicz PI; Montorsi F; Huland H; Chun FK
Eur Urol; 2008 Apr; 53(4):750-7. PubMed ID: 17964070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
